- New, groundbreaking technology delivers Illumina's most
comprehensive genome yet; early results from Broad
Clinical Labs demonstrate a highly simplified workflow,
ultra-long phasing, high-resolution insights into complex genomic
variation, and enhanced long-range information
- Illumina and customers will also showcase new details on
complete proteomics solution and latest data on Fluent single-cell
technology
SAN
DIEGO, Oct. 31, 2024 /PRNewswire/ -- Illumina,
Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and
array-based technologies, today announced that it will present
updates on several key innovations in whole-genome sequencing,
proteomics, and single-cell technology at the American Society of
Human Genetics (ASHG) Annual Meeting next week in Denver. The latest details will be presented
alongside new data from key opinion leaders in next-generation
sequencing (NGS), illustrating the potential impact of Illumina's
emerging innovations.
First-of-its-kind technology streamlines whole-genome
workflows, expands genomic insights
In a mainstage presentation on November
6, Steve Barnard, PhD, chief
technology officer, will reveal new details on the company's
constellation mapped read technology, originally announced in the
company's August 2024 strategy update
as the "comprehensive genome." Currently under development, this
novel technology is designed to streamline whole-genome workflows
and eliminate traditional library prep.
Additionally, constellation mapped read technology will deliver
Illumina's most comprehensive whole genome yet, adding long-range
information to Illumina's proven, highly accurate
XLEAP-SBS™ chemistry. The expanded insights from
this proprietary technology will resolve challenging genic regions,
such as pseudogenes, while generating ultra-long phased data and
providing a high-resolution view of complex structural
variation.
"These are unprecedented, breakthrough technologies that will
power our future comprehensive whole-genome solutions," Barnard
said. "We believe this solution could be the de facto genome of the
future, offering expanded information and simplicity for labs."
Barnard will be joined on stage by Niall
Lennon, PhD, chair and chief scientific officer of Broad
Clinical Labs, who will present early data on the flexibility and
capabilities of the technology.
The first product based on constellation mapped read technology
is set to begin early access in the first half of 2025.
Illumina Protein Prep: A complete NGS-based proteomics
solution
On November 7, Illumina will
present updates on its proteomics solution, Illumina Protein Prep,
which delivers sample-to-analysis protein discovery. The solution
is an outcome of Illumina's partnership with Standard BioTools
(formerly SomaLogic), announced in 2022.
Proteomics enables the observation of direct cellular function
to gain insights on protein-driven disease traits, and the
inclusion of proteomics in Illumina's NGS portfolio provides
visibility into the entire biological process. The presentation
will highlight the early access solution's ability to identify and
quantify more than 6000 human proteins and its readout
compatibility with NovaSeq™ X and NovaSeq 6000
Systems to enable multiomics on a single platform—a key
differentiator from existing proteomics methodologies.
Kamel Lahouel, PhD, assistant professor in the Early Detection
and Prevention Division at The Translational Genomics Research
Institute (TGen), part of City of Hope, will present on a new pilot
study using Illumina Protein Prep to investigate the potential of
circulating protein concentrations as biomarkers for cancer
detection. TGen is part of an early access, limited release program
for the solution with select customers.
When it launches in early 2025, Illumina Protein Prep will
feature 9000 unique human proteins.
Leading single-cell technology: Fluent PIPseq™
V
On November 7, Illumina will
showcase PIPseq V, a single-cell analysis solution currently on the
market from Fluent BioSciences, an Illumina company. In a
collaborative talk, experts will discuss how PIPseq V enables
researchers to delve deeper into the complexities of cell biology
with a scalable, accessible solution. Presenters will share early
access data and insights from a large study on more than 1 million
neuronal single cells using PIPseq V.
Additional updates
Barnard's presentation on November
6 will also cover the latest updates on 25B 100-cycle and 200-cycle kits for the NovaSeq
X Series, which will be available by end of year. The kits will be
a key enabler of multiomics, allowing customers to perform
single-cell, proteomics, and other applications at scale.
"We look forward to expanding on these innovations with our
customers and peers at ASHG," Barnard said. "We also look forward
to sharing our latest instruments, the MiSeq™
i100 Series, with our fellow NGS enthusiasts at our booth."
Illumina's new MiSeq i100 Series will be on display at booth 503
during the meeting, and Illumina will be presenting scientific
findings in five poster presentations and abstracts.
Use of forward-looking statements
This release may contain forward-looking statements that involve
risks and uncertainties. Among the important factors to which our
business is subject that could cause actual results to differ
materially from those in any forward-looking statements are: (i)
challenges inherent in developing and launching new products and
services, including modifying and scaling manufacturing operations,
and reliance on third-party suppliers for critical components; (ii)
our ability to manufacture robust instrumentation and consumables;
and (iii) the acceptance by customers of our newly launched
products, which may or may not meet our and their expectations,
together with other factors detailed in our filings with the
Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in
public conference calls, the date and time of which are released
beforehand. We undertake no obligation, and do not intend, to
update these forward-looking statements, to review or confirm
analysts' expectations, or to provide interim reports or updates on
the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as a global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit illumina.com and connect with us on X,
Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli
Schwartz
858-291-6421
IR@illumina.com
Media:
Christine
Douglass
PR@illumina.com
View original
content:https://www.prnewswire.com/news-releases/illumina-to-preview-newest-innovations-in-ngs-and-multiomic-technologies-at-the-american-society-of-human-genetics-annual-meeting-302292671.html
SOURCE Illumina, Inc.
